CA2497539A1 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors - Google Patents
Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors Download PDFInfo
- Publication number
- CA2497539A1 CA2497539A1 CA002497539A CA2497539A CA2497539A1 CA 2497539 A1 CA2497539 A1 CA 2497539A1 CA 002497539 A CA002497539 A CA 002497539A CA 2497539 A CA2497539 A CA 2497539A CA 2497539 A1 CA2497539 A1 CA 2497539A1
- Authority
- CA
- Canada
- Prior art keywords
- aryl
- compound
- alkyl
- group
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40818202P | 2002-09-04 | 2002-09-04 | |
| US60/408,182 | 2002-09-04 | ||
| PCT/US2003/027564 WO2004022062A1 (en) | 2002-09-04 | 2003-09-03 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2497539A1 true CA2497539A1 (en) | 2004-03-18 |
Family
ID=31978574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002497539A Abandoned CA2497539A1 (en) | 2002-09-04 | 2003-09-03 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7084271B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1545533A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2006500391A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050057072A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1694705A (cg-RX-API-DMAC7.html) |
| AR (1) | AR041135A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003265901B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2497539A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05002574A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ539163A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20040998A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200412966A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004022062A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200501854B (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AR049769A1 (es) * | 2004-01-22 | 2006-09-06 | Novartis Ag | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| WO2005112936A1 (en) * | 2004-05-14 | 2005-12-01 | The Regents Of The University Of Michigan | Compositions and methods relating to protein kinase inhibitors |
| CA2576159A1 (en) * | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
| JP5334414B2 (ja) * | 2004-09-06 | 2013-11-06 | バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のピラゾロピリミジン |
| JP5130053B2 (ja) | 2005-01-05 | 2013-01-30 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリアゾロフタラジン |
| MX2007008137A (es) | 2005-01-05 | 2007-07-19 | Altana Pharma Ag | Triazoloftalazinas como inhibidores de pde2. |
| WO2007005541A2 (en) * | 2005-06-30 | 2007-01-11 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Small molecule inhibitors against west nile virus replication |
| CA2621983A1 (en) * | 2005-09-09 | 2007-03-22 | Schering Corporation | Azafused cyclin dependent kinase inhibitors |
| JP2010504933A (ja) * | 2006-09-29 | 2010-02-18 | ノバルティス アーゲー | Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン |
| AU2007307489A1 (en) * | 2006-10-06 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Combination drug |
| WO2011028638A1 (en) | 2009-09-04 | 2011-03-10 | Schering Corporation | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012149157A2 (en) | 2011-04-26 | 2012-11-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2014066795A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2014066743A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| RU2015143517A (ru) * | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
| JP6545197B2 (ja) * | 2014-05-28 | 2019-07-17 | ノバルティス アーゲー | 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用 |
| CN108700594B (zh) | 2015-11-18 | 2021-06-29 | 建新公司 | 多囊性肾病的生物标志物及其用途 |
| IL317854A (en) | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| CN113248500B (zh) * | 2021-06-10 | 2021-10-19 | 中国药科大学 | 氮杂吲哚嘧啶胺杂环化合物及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4116288Y1 (cg-RX-API-DMAC7.html) | 1964-11-07 | 1966-07-28 | ||
| DE69130683T2 (de) | 1991-04-22 | 1999-05-06 | Otsuka Pharmaceutical Factory, Inc., Naruto, Tokushima | PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL |
| US5571813A (en) | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
| EP0628559B1 (en) | 1993-06-10 | 2002-04-03 | Beiersdorf-Lilly GmbH | Pyrimidine compounds and their use as pharmaceuticals |
| GB9325074D0 (en) * | 1993-12-07 | 1994-02-02 | Zeneca Ltd | Bicyclic heterocycles |
| EP0714898B1 (en) | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
| US5502137A (en) | 1994-11-25 | 1996-03-26 | Eastman Chemical Company | Polyether glycols and alcohols derived from 3,4-epoxy-1-butene, tetrahydrofuran and an initiator |
| US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6413974B1 (en) | 1998-02-26 | 2002-07-02 | Aventis Pharmaceuticals Inc. | 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines |
| DK1140938T3 (da) | 1999-01-11 | 2003-12-22 | Univ Princeton | Højaffinitetsinhibitorer for målvalidering og anvendelser heraf |
| EP1199306B1 (en) | 1999-07-26 | 2005-12-07 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| FR2805160B1 (fr) | 2000-02-23 | 2002-04-05 | Oreal | Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture |
| WO2002010162A1 (en) | 2000-07-26 | 2002-02-07 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| US7067520B2 (en) | 2000-11-17 | 2006-06-27 | Ishihara Sangyo Kaisha, Ltd. | Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts |
| FR2817469B1 (fr) | 2000-12-04 | 2003-04-18 | Oreal | Composition de coloration, procede d'obtention et utilisation pour la coloration de fibres keratiniques |
| JP2004516297A (ja) | 2000-12-20 | 2004-06-03 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) | サイクリン依存性キナーゼ(cdk)及びグリコーゲンシンターゼキナーゼ−3(gsk−3)の阻害剤 |
| CA2483306A1 (en) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
| DE10223917A1 (de) | 2002-05-29 | 2003-12-11 | Bayer Cropscience Ag | Pyrazolopyrimidine |
-
2003
- 2003-09-03 EP EP03794594A patent/EP1545533A1/en not_active Withdrawn
- 2003-09-03 KR KR1020057003548A patent/KR20050057072A/ko not_active Withdrawn
- 2003-09-03 AR ARP030103190A patent/AR041135A1/es unknown
- 2003-09-03 US US10/654,163 patent/US7084271B2/en not_active Expired - Fee Related
- 2003-09-03 WO PCT/US2003/027564 patent/WO2004022062A1/en not_active Ceased
- 2003-09-03 MX MXPA05002574A patent/MXPA05002574A/es active IP Right Grant
- 2003-09-03 AU AU2003265901A patent/AU2003265901B2/en not_active Ceased
- 2003-09-03 JP JP2004534490A patent/JP2006500391A/ja not_active Ceased
- 2003-09-03 NZ NZ539163A patent/NZ539163A/en unknown
- 2003-09-03 TW TW092124350A patent/TW200412966A/zh unknown
- 2003-09-03 CA CA002497539A patent/CA2497539A1/en not_active Abandoned
- 2003-09-03 CN CNA038249081A patent/CN1694705A/zh active Pending
- 2003-09-04 PE PE2003000898A patent/PE20040998A1/es not_active Application Discontinuation
-
2005
- 2005-03-03 ZA ZA200501854A patent/ZA200501854B/en unknown
-
2006
- 2006-03-31 US US11/395,965 patent/US7468372B2/en not_active Expired - Fee Related
-
2011
- 2011-01-13 JP JP2011005344A patent/JP2011074088A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW200412966A (en) | 2004-08-01 |
| WO2004022062A1 (en) | 2004-03-18 |
| US20060173017A1 (en) | 2006-08-03 |
| US20040102452A1 (en) | 2004-05-27 |
| JP2011074088A (ja) | 2011-04-14 |
| AU2003265901B2 (en) | 2006-09-14 |
| ZA200501854B (en) | 2005-09-12 |
| KR20050057072A (ko) | 2005-06-16 |
| JP2006500391A (ja) | 2006-01-05 |
| US7084271B2 (en) | 2006-08-01 |
| AR041135A1 (es) | 2005-05-04 |
| CN1694705A (zh) | 2005-11-09 |
| NZ539163A (en) | 2007-03-30 |
| AU2003265901A1 (en) | 2004-03-29 |
| PE20040998A1 (es) | 2004-12-30 |
| EP1545533A1 (en) | 2005-06-29 |
| MXPA05002574A (es) | 2005-09-08 |
| US7468372B2 (en) | 2008-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2497544A1 (en) | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors | |
| CA2497444A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| CA2497450A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| CA2499756A1 (en) | Imidazopyrazines as cyclin dependent kinase inhibitors | |
| CA2555345A1 (en) | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| CA2497440A1 (en) | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors | |
| MXPA05003119A (es) | Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas. | |
| CA2499639A1 (en) | Imidazopyridines as cyclin dependent kinase inhibitors | |
| CA2499593A1 (en) | Pyrazolopyridines as cyclin dependent kinase inhibitors | |
| CA2665539A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| CA2665543A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | |
| CA2557184A1 (en) | Pyrazolotriazines as kinase inhibitors | |
| RU2008150419A (ru) | ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ CDK | |
| RU2008117295A (ru) | Новые пиразолопиримидины как ингибиторы циклинзависимых киназ | |
| RU2008122967A (ru) | Имидазопиразины в качестве ингибиторов протеинкиназ | |
| EP3194368B1 (en) | Benzo-heterocyclic compounds and their applications | |
| ZA200501854B (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors. | |
| JP2006507253A5 (cg-RX-API-DMAC7.html) | ||
| ZA200501855B (en) | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors | |
| JP2006503838A5 (cg-RX-API-DMAC7.html) | ||
| JP2004510733A5 (cg-RX-API-DMAC7.html) | ||
| WO2011153383A1 (en) | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound | |
| CA2424797A1 (en) | Methods of inducing cancer cell death and tumor regression | |
| RU2009127775A (ru) | Способ введения пегилированного липосомального доксорубицина | |
| JP2006500391A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |